title: Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study.
abstract: The VIPE study was a prospective, non-comparative, open-label clinical evaluation of 97 hypertensive patients (69.1% female; 68.9 +/- 9.5 years; mean blood pressure (BP) 160 +/- 12/90 +/- 9 mmHg) with echocardiographic evidence of left ventricular hypertrophy (LVH). Patients were treated for six months with a candesartan-based regimen (8 mg/16 mg + HCTZ 12.5 mg + additional drugs to lower BP < 140/90 mmHg). After six months, systolic/diastolic BP was decreased by 19.3 +/- 8/9.4 +/- 5 mmHg (p<0.001 for both), and left ventricular mass index (LVMI) decreased 17.01 g/m2 (95%CI: -13.2 to -20.99; p<0.001). During treatment with the candesartan-based regimen all echocardiographic parameters related to LVMI were significantly reduced and 28% achieved a target LVMI [< 134 g/m(2) (men) and < 110 g/m(2) (women)]. No significant changes were observed in ejection fraction, shortening fraction or LV diastolic function. Univariate analysis showed that both age (p=0.03) and diabetes (p=0.029) were predictive of LVH regression. Thus, a candesartan-based regimen for six months significantly reduced echocardiographic LVH in hypertensive patients in general practice. The drug was very well tolerated and no serious adverse events were reported.
authors.affiliation: Department of Cardiology, Hospital Ramón y Cajal, Ctra. Colmenar km. 9.100, Madrid 28034, Spain. vbarriosa@meditex.es
authors.forename: Vivencio
authors.initials: V
authors.lastname: Barrios
authors.forename: Carlos
authors.initials: C
authors.lastname: Escobar
authors.forename: Alberto
authors.initials: A
authors.lastname: Calderón
authors.forename: Juan Pablo
authors.initials: JP
authors.lastname: Tomás
authors.forename: Soledad
authors.initials: S
authors.lastname: Ruiz
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Moya
authors.forename: Alicia
authors.initials: A
authors.lastname: Megías
authors.forename: Onofre
authors.initials: O
authors.lastname: Vegazo
authors.forename: Raúl
authors.initials: R
authors.lastname: Fernandez
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D004359:Drug Therapy, Combination; D015150:Echocardiography, Doppler; D005260:Female; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C081643:candesartan